E 3040
Latest Information Update: 20 Aug 1999
At a glance
- Originator Eisai Co Ltd
 - Class
 - Mechanism of Action Lipoxygenase inhibitors; Thromboxane synthase inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Ulcerative colitis